D-α-tocopherol polyethylene glycol succinate-based redox-sensitive paclitaxel prodrug for overcoming multidrug...

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Oncology

Background:

• Multidrug resistance (MDR) limits the efficacy of P-glycoprotein (P-gp) substrate anticancer drugs like paclitaxel (PTX).
• Developing strategies to overcome P-gp mediated MDR is crucial for improving cancer treatment outcomes.

Purpose of the Study:

• To synthesize and evaluate a novel dual-functional prodrug, TPGS-S-S-PTX, for synergistic P-gp inhibition and intracellular redox-sensitive drug release.
• To assess the potential of TPGS-S-S-PTX in overcoming paclitaxel resistance in ovarian cancer models.

Main Methods:

• Synthesis of D-α-tocopherol polyethylene glycol succinate (TPGS) based PTX prodrug (TPGS-S-S-PTX).
• Characterization of self-assembled micelle formation and drug release under physiological and reductive conditions.
• In vitro cytotoxicity assays using PTX-resistant human ovarian cell line (A2780/T) and in vivo tumor growth inhibition studies.

Main Results:

• TPGS-S-S-PTX self-assembled into stable micelles (∼140 nm) and rapidly released PTX and TPGS derivatives in reductive environments.
• Enhanced PTX accumulation and significant cytotoxicity were observed in A2780/T cells, with IC50 values superior to Taxol and TPGS-C-C-PTX.
• In vivo studies showed extended half-life, increased AUC, enhanced tumor distribution, significant tumor growth inhibition, and reduced side effects for TPGS-S-S-PTX.

Conclusions:

• The novel TPGS-S-S-PTX prodrug effectively overcomes P-gp mediated multidrug resistance through combined P-gp inhibition and targeted drug release.
• TPGS-S-S-PTX demonstrates significant potential for improving the therapeutic efficiency of paclitaxel in treating multidrug-resistant tumors.